Arab Journal of Gastroenterology
Volume 10, Issue 4, Supplement , Pages S7-S9 , April 2010

New developments in the treatment of chronic hepatitis B

References 

  1. Chang TT, Gish R, De Man R, et al. A comparison of entecavir and mivudine for HBeAg-positive chronic hepatitis B. New Engl J Med. 2006;354:1001–1010
  2. Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. In: Program and abstracts of the 42nd annual meeting of the European association for the study of the liver. Barcelona, Spain: April 11–15, 2007 [Abstract 781].
  3. DiBisgelie AM, Lai CL, Gane E, Chen Y-C, Thongsawar S, Wang Y, et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal 2-year efficacy. Hepatology. 2006;44(4 Suppl. 1):230A
  4. Gane E, Lai CL, Min A, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study. In: Program and abstracts of the 42nd annual meeting of the European association for the study of the liver. Barcelona, Spain: April 11–15, 2007 [Abstract 493].
  5. Hadziyannis AS, Mitsoula P, Hadziyannis E. Monitoring serum HBV DNA levels with the TaqMan technique during treatment of HBeAg(−) chronic hepatitis B with lamivudine. Hepatology. 2005;42(4 Suppl 1):726A
  6. Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2006;6(9):913–921
  7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology. 2006;131(6):1743–1751
  8. Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs. 2007;16(6):777–786
  9. Han SH, Lai CL, Gane E, Liaw YF, Thongsawat S, Wang Y et al.Telbivudine GLOBE trial year two: efficacy, safety and predictors of outcome in patients with chronic hepatitis B. Presented at DDW Washington DC, USA: May 19–24, 2007.
  10. Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. In: Program and abstracts of the 58th annual meeting of the American association for the study of liver diseases. Boston, Massachusetts: November 2–6, 2007 [Abstract LB6].
  11. Hoofnagle JH. Hepatitis B – preventable and now treatable. New Engl J Med. 2006;354:1074–1076
  12. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129
  13. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890–897
  14. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–536
  15. Lai C, Gane E, Hsu C, et al. Two-year results from GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. In: Program and abstracts of the 57th annual meeting of the American association for the study of liver diseases. Boston, Massachusetts: October 27–31, 2006 [Abstract 91].
  16. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med. 2005;352:2682–2695
  17. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  18. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254–265
  19. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. New Engl J Med. 2004;351:1206–1217
  20. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. In: Program and abstracts of the 58th annual meeting of the American association for the study of liver diseases. Boston, Massachusetts: November 2–6, 2007 [Abstract LB2].
  21. Marcellin P, Chan HLY, Lai CL, Cho M, Moon YM, Chao Y, et al. 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine. J Hepatol. 2007;46(Suppl. 1):S55
  22. Entecavir Rivkin A. A new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today (Barc.). 2007;43(4):201–220
  23. Ruiz-Sancho A, Sheldon J, Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007;7(5):751–761
  24. Standring DN, Patty A, Chapron C, et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the international GLOBE trial. In: Program and abstracts of digestive disease week. Washington, DC: May 19–24, 2007 [Abstract S1781].
  25. Tan F, Wong SN, Hussain MT, Oberhelman K, Lok A. Tenofovir (TDF) monotherapy is effective in suppressing serum HBV DNA in chronic hepatitis B (CHB) patients with primary nonresponse to adefovir (ADV) but not those with ADV-resistant HBV. In: Program and abstracts of digestive disease week. Washington, DC: May 19–24, 2007 [Abstract 95].
  26. Van Bommel F, Brodzinski A, Mihm U, Jung MC, Sarrazin C, Bergk A, et al. Multifactorial analysis of host and virus related risk factors for the development of viral resistance during long-term lamivudine treatment of HBV infection over up to nine years. J Hepatol. 2007;46(Suppl.1):S198
  27. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34(4 Pt. 1):785–791

PII: S1687-1979(09)00318-9

doi: 10.1016/j.ajg.2009.12.011

Arab Journal of Gastroenterology
Volume 10, Issue 4, Supplement , Pages S7-S9 , April 2010

Article Tools